PRIME THERAPEUTICS for PRIME THERAPEUTICS
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report | Oct 19, 2026 | $140,000 | Replaced |
| 3rd Quarter - Amendment (this page) | Oct 19, 2026 | $140,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices S. 2355 Patients Deserve Price Tags Act provisions related to drug price transparency and patient transparency tools S. 3822 Break Up Big Medicine Act provisions related to insurer/PBM ownership or pharmacies S. 1954/HR 5526 The Biosimilar Red Tape Elimination Act - provisions related to interchangeability of biosimilars H.R.9393 Lower Costs, More Transparency Act of 2026
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID ROOT | — |
Medicare/Medicaid MMM
H.R. 8143 Ensuring Access to Lower Cost Medicines for Seniors Act of 2026 provisions related to formulary placement of certain drugs. H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices H.R. 1227, Alternatives to PAIN Act requirements related to formulary Tierring and prior authorization in Medicare Part D for non-opioid pain medications.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID ROOT | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.